A recent Phase II trial of the COX-2 inhibitor celecoxib (Celebrex/Pfizer) showed that this agent “had no effect on intermediate biomarkers of prostate carcinogenesis.”
Filed under: Drugs in development, Prevention | Tagged: celecoxib, COX-2, Prevention | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site
